Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds

Abimael Cruz-Migoni,Peter Canning,Camilo E. Quevedo,Carole J. R. Bataille,Nicolas Bery,Ami Miller,Angela J. Russell,Simon E. V. Phillips,Stephen B. Carr,Terence H. Rabbitts

DOI: https://doi.org/10.1073/pnas.1811360116

IF: 11.1

2019-01-25

Proceedings of the National Academy of Sciences

Abstract:Significance The RAS family of oncogenic proteins is important as therapy targets because of the frequency of activating mutations in almost all major cancers. An important approach is development of small molecules with drug-like properties that can inhibit RAS-effector protein interactions inside cells. We present a strategy for identification of such compounds, and their development as RAS-effector interaction inhibitors, utilizing a structure-based design approach and cell-based assays. By combining moieties from two distinct sets of RAS-binding molecules, we generated cross-over compounds that showed improved efficacy in vitro and in cell-based assays.

multidisciplinary sciences